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Abstract
Tight junctions between intestinal epithelial cells mediate the permeability of the intestinal barrier, and loss of intestinal
barrier function mediated by TNF signaling is associated with the inflammatory pathophysiology observed in Crohn’s
disease and celiac disease. Thus, factors that modulate intestinal epithelial cell response to TNF may be critical for the
maintenance of barrier function. TNF alpha-induced protein 3 (TNFAIP3) is a cytosolic protein that acts in a negative
feedback loop to regulate cell signaling induced by Toll-like receptor ligands and TNF, suggesting that TNFAIP3 may play a
role in regulating the intestinal barrier. To investigate the specific role of TNFAIP3 in intestinal barrier function we assessed
barrier permeability in TNFAIP3
2/2 mice and LPS-treated villin-TNFAIP3 transgenic mice. TNFAIP3
2/2 mice had greater
intestinal permeability compared to wild-type littermates, while villin-TNFAIP3 transgenic mice were protected from
increases in permeability seen within LPS-treated wild-type littermates, indicating that barrier permeability is controlled by
TNFAIP3. In cultured human intestinal epithelial cell lines, TNFAIP3 expression regulated both TNF-induced and myosin light
chain kinase-regulated tight junction dynamics but did not affect myosin light chain kinase activity. Immunohistochemistry
of mouse intestine revealed that TNFAIP3 expression inhibits LPS-induced loss of the tight junction protein occludin from
the apical border of the intestinal epithelium. We also found that TNFAIP3 deubiquitinates polyubiquitinated occludin.
These in vivo and in vitro studies support the role of TNFAIP3 in promoting intestinal epithelial barrier integrity and
demonstrate its novel ability to maintain intestinal homeostasis through tight junction protein regulation.
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Introduction
One of the functions of intestinal epithelial cells (IECs), in
addition to nutrient and water absorption, is to provide a dynamic,
semi-permeable barrier regulated by tight junctions (TJs) between
adjacent epithelial cells. This selectivity provides for the control of
antigen traffic through the mucosa and facilitates interaction
between bacterial flora and the mucosal immune system [1].
Inflammatory bowel disease (IBD) is characterized by an abnormal
response to these antigens and a persistent inflammatory state [2].
Alterations in barrier function have been implicated in murine
models of IBD [3,4,5,6]. Patients with Crohn’s disease, ulcerative
colitis or celiac disease, and some of their first-degree healthy
relatives, have increased intestinal permeability [7–9], suggesting
that decreased barrier function may predispose or contribute to
the intestinal pathology of these diseases.
The acute regulation of intestinal permeability by TNF is
mediated by the activation of myosin light chain kinase (MLCK)
and tight junction remodeling [10,11]. Antigen passage across the
epithelium can activate lamina propria immune cells, resulting in the
secretion of TNF and an increase in MLCK activity [10]. This
induces changes in epithelial cell tight junctions, including the
redistribution of perijunctional actin, ZO-1, claudin, and occludin
from the tight junction complex, causing an increase in paracellular
flux [11]. Occludin is a tight junction transmembrane protein that
both regulates and organizes the tight junction structure [1]. Tight
junctions are dynamic and occludin is mobile, diffusing within the
junction at the membrane [12]. Occludin ubiquitination is sufficient
for the disruption of the junction (including relocalization of claudins
and ZO-1) and occludin internalization results in its degradation
[13]. Additionally, occludin endocytosis is essential for TNF-induced
tight junction regulation [14]. Ubiquitination of membrane proteins
can initiate their internalization and endocytic trafficking. Mice with
constitutively active MLCK display increased barrier permeability,
inflammatory cytokine production and are more susceptible to
IBD [15]. Patients with Crohn’s disease have increased intestinal
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pathway in the reduced barrier function that is a feature of IBD [16].
Therefore, factors that control TNF-induced changes in IEC TJs
may play critical roles in barrier function and the prevention of IBD.
TNF alpha-induced protein 3 (TNFAIP3, also known as A20) is
an ubiquitin-modifying enzyme that negatively regulates TNF and
TLR responses [17,18,19]. Its expression is rapidly induced by NF-
kB activation, and TNFAIP3 acts in a negative feedback loop to
control its own expression, along with the production of
inflammatory mediators [17,20]. The N-terminal half of TNFAIP3
encodes a deubiquitinating (DUB) domain, whereas the C-terminal
half encodes a zinc finger-containing E3 ligase domain. These two
enzymatic activities work together to control the ubiquitination and
subsequent degradation of cellular substrates [18]. The TNFAIP3
DUB domain can remove K63-linked polyubiquitin chains from
NF-kB signaling molecules, and its E3 ligase domain can mediate
the formation of K48-linked polyubiquitin chains that target the
substrate to the proteasome for degradation, thereby terminating
inflammatory pathways [17,18]. DUB activity must precede
subsequent E3 ligase activity for degradation to occur, but the
removal of K63-linked polyubiquitin chains from a target protein
does not necessarily lead to K48-linked polyubiquitination and
degradation [21]. TNF induces TNFAIP3 expression in all tissues
including mouse and human intestinal epithelial cells [19,22,23,24].
Mice with a global deletion of TNFAIP3 are hypersensitive to
LPS and TNF, develop multi-organ inflammation (including
intestinal inflammation), and die prematurely [17,19]. Mice
lacking TNFAIP3 specifically in IECs do not develop spontaneous
gut inflammation, but are susceptible to a dextran sodium sulfate-
induced model of colitis [22]. Mucosal biopsies from Crohn’s
disease patients with moderate to severe disease are characterized
by low TNFAIP3 expression [25]. Furthermore the TNFAIP3 gene
(located on chromosome 6q23) has been identified as a
susceptibility locus in genome-wide association studies for several
human autoimmune inflammatory disorders including IBD, celiac
disease, psoriasis, lupus, rheumatoid arthritis and type I diabetes
[26,27,28] [29,30,31,32,33,34]. We have recently demonstrated
an association of a nonsynonymous TNFAIP3 polymorphism
(rs5029941) with IBD risk in African-Americans [35]. This
functional SNP alters the ability of TNFAIP3 to DUB TNF-
receptor associated protein 2 (TRAF2). Collectively, these studies
point to a role for TNFAIP3 in limiting inflammation in various
diseases that is likely cell and context-dependent. Several of these
TNFAIP3-associated diseases including type 1 diabetes, celiac
disease and inflammatory bowel disease, are known to involve loss
of intestinal barrier function [36,37,38]. Although TNFAIP3 is
expressed in human IEC and has been identified as a protein of
interest in intestinal disease, it is not known whether TNFAIP3
plays a role in barrier function, or the regulation of tight junctions
by TNF. The objective of this study was therefore to determine the
role of TNFAIP3 expression in IEC tight junction regulation and
intestinal permeability. Our results indicate that TNFAIP3
promotes intestinal barrier function and regulates TJ dynamics,
including the redistribution and ubiquitination of occludin.
Results
TNFAIP3 is required for intestinal barrier function
Factors that modulate IEC response to TNF may be critical for
the maintenance of barrier function [10]. TNFAIP3 inhibits TNF-
induced signaling pathways; therefore, we examined whether
TNFAIP3 plays a central role in regulating IEC barrier
permeability. To investigate the role of TNFAIP3 in maintaining
the intestinal barrier we assessed barrier integrity in TNFAIP3
2/2
mice. These mice spontaneously develop inflammation that is
driven by TLR-dependent signals originating from endogenous
microbiota [17,19,39]. Immunohistochemistry for the intestinal
epithelial tight junction protein occludin revealed characteristic
morphological features of epithelial tight junction disruption,
including the loss of occludin localization from the apical surface
in intestinal tissue taken from unperturbed TNFAIP3
2/2 mice
(Figure 1). Further evidence for epithelial tight junction disruption
was observed when measuring flux of FITC-dextran out of
explanted intestinal loops from TNFAIP3
2/2 mice compared with
that of wild-type (WT) mice. WT mice showed a minimal change
in flux over time indicating an intact intestinal barrier, while
TNFAIP3
2/2 mice had a more pronounced increase in flux
indicating greater intestinal permeability in these mice (Figure 2).
Thus, TNFAIP3 is required for the maintenance of intestinal
barrier function in vivo. As TNFAIP3 normally restricts inflam-
matory TLR signals and its expression is induced in a variety of
tissue types [17,19,39], the increased gut permeability in
TNFAIP3
2/2 mice might reflect an indirect effect of ongoing
inflammation in these mice, a direct role for TNFAIP3 in IEC TJ
stability, or a combination of these two effects.
To assess the direct role of IEC expression of TNFAIP3 in
barrier function we generated villin-TNFAIP3 mice that consti-
tutively overexpress a TNFAIP3 transgene in the IECs of the small
intestine, cecum and colon (Figures S1, S2). Villin-TNFAIP3 mice
are healthy and display normal growth and reproduction up to 6
months of age. We stimulated inflammation in WT and villin-
TNFAIP3 mice by injecting LPS into the peritoneal cavity 45
minutes prior to euthanasia. LPS induces a systemic inflammatory
Figure 1. TNFAIP3 supports occludin localization at intestinal tight junctions. Immunohistochemistry for occludin (green), actin (red) and
DNA (blue) is shown in intestines of untreated wild type (WT) and TNFAIP3
2/2 mice. A lack of typical perijunctional occludin localization can be
observed at the apical surface of epithelial cells in the TNFAIP3 deficient mice.
doi:10.1371/journal.pone.0026352.g001
TNFAIP3 and Tight Junctions
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term effects are mediated largely by the induction of TNF release
from innate immune cells, as well as enterocytes in vitro [40–41]. LPS
induces endogenous TNF release which, when overproduced by
intestinal epithelial cells, causes an IBD pathology [42]. The LPS
challenge induced greater transepithelial flux of FITC-dextran
across the ileum in explanted loops from WT mice compared to
villin-TNFAIP3 mice, indicating that epithelial-specific overexpres-
sion of TNFAIP3 promotes resistance to inflammatory disruption of
the intestinal barrier (Figure 3). Occludin is removed from apical
sites of the epithelium and internalized in LPS-treated mice, and
recent studies implicate occludin relocation by endocytosis in TNF-
induced barrier permeability [14,43]. Similar to these previously
published reports, we observed occludin loss from the apical surface
and an overall diminution of occludin intensity in IEC following
administration of LPS to WT mice; however, occludin loss was
markedly reduced in the intestine of LPS-treated villin-TNFAIP3
mice (Figure 4). This prevention of occludin redistribution suggests a
mechanism by which TNFAIP3 affects the structure or integrity of
tight junctions in IECs. Together these results demonstrate that
TNFAIP3 is required for the maintenance of intestinal barrier
function and that TNFAIP3 plays an important role in modulating
epithelialpermeability,inpartby controlling occludin localization or
stability in IEC.
TNFAIP3 expression in IEC controls TNF-induced
decreases in barrier function
To test whether TNFAIP3 plays a direct role in the regulation of
IEC tight junction integrity, we infected the IEC line HCT116 with
lentivirus containing the TNFAIP3 cDNA in order to generate
epithelial cell lines that stably and constitutively overexpress
TNFAIP3 (Figure S3). IECs grown in semi-permeable supports
were treated with TNF in the basolateral compartment and barrier
function was assessed by changes in transepithelial electrical
resistance (TER) over time. TNF induced a TER drop of ,15%
(p,0.001) within 1 hour in cells expressing the control GFP vector,
but this TER drop was blocked in cells overexpressing TNFAIP3
(Figure 5A). Using annexin V and propidium iodide staining we did
not observe any differences in the number of dead or apoptotic cells
overa similartime course,consistentwith the inabilityofTNFalone
to induce death in most cell types (Figure S4) [44]. Thus, the
heterologous expression of TNFAIP3 in IECs can prevent TNF-
induced decreases in barrier function in these cells.
To determine if TNFAIP3 expression is required for IEC
barrier function, we infected cells with lentivirus containing
TNFAIP3 shRNA constructs to generate stable pools of cells with
decreased expression of TNFAIP3 (Figure S3). Cells expressing
TNFAIP3 shRNA displayed a more pronounced decrease in TER,
compared to cells expressing scrambled shRNA, following
exposure to TNF in culture (Figure 5B). The difference in the
TER change between IECs expressing scrambled shRNA
compared with TNFAIP3 shRNA did not result from differences
in cell death between the two cell lines (Figure S4). Thus, our
studies demonstrate that TNFAIP3 expression plays a direct role
in IEC to maintain barrier function during exposure to TNF in
vitro.
TNFAIP3 regulates barrier function downstream of MLCK
The control of tight junction dynamics that maintain IEC
barrier function is not entirely understood, but MLCK plays a key
role in the reduction of TJ integrity in response to TNF in IECs
[45]. To assess whether the drop in TER associated with
TNFAIP3 deficiency involved dysregulation of the MLCK
signaling pathway, we treated cells with membrane-permeant
inhibitor of myosin light chain kinase (PIK), a highly specific
inhibitor of MLCK activity in IEC [46]. PIK did not directly
inhibit TNFAIP39s deubiquitinating activity and did not signifi-
cantly change the TER of untreated cells (Figures S5, S6). As
before, TNF induced a rapid decrease in TER in scrambled
shRNA-expressing cells, and this decrease was more pronounced
in TNFAIP3 shRNA-expressing cells. Inhibition of MLCK by PIK
completely prevented the rapid decrease in TER in both
scrambled and TNFAIP3 deficient cells (Figure 6A). This suggests
that TNFAIP3 regulates barrier function by acting at some point
Figure 3. Intestinal epithelial cell-specific expression of
TNFAIP3 protects against LPS-induced loss of barrier function.
Explanted intestinal loops from WT (triangles) or villin-TNFAIP3
transgenic mice (squares) were assayed for barrier function beginning
45 minutes after injection of LPS (0.1 mg/mouse, ,5 mg/kg i.p.; filled
symbols) or in untreated animals (open symbols). The flux of FITC-
dextran over time out of the loops was measured in relative fluorescent
units (RFU) per cm of intestinal tissue. Increased FITC-dextran flux
indicates decreased barrier function. (*p,0.05, ***p,0.001; WT
untreated vs. WT LPS treated).
doi:10.1371/journal.pone.0026352.g003
Figure 2. TNFAIP3 is required to maintain intestinal barrier
function. Explanted intestinal loops from untreated wild type (WT;
triangles) and TNFAIP3 deficient mice (TNFAIP3
2/2; circles) were
examined for loss of barrier function. The flux of FITC-dextran over
time out of the loops was measured in relative fluorescent units (RFU)
per cm of intestinal tissue. Increased FITC-dextran flux indicates
decreased barrier function. (***p,0.001).
doi:10.1371/journal.pone.0026352.g002
TNFAIP3 and Tight Junctions
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chain (MLC) is a standard indicator of MLCK activity [10]. We
therefore assessed phospho-MLC levels in TNF-treated cells to
determine whether TNFAIP3 inhibits TNF-induced MLCK
activation. Cells constitutively expressing TNFAIP3 did not
display altered phosphorylation of MLC in response to TNF
treatment (Figure 6B). These data suggest that TNFAIP3 regulates
MLCK-mediated barrier function through a mechanism that does
not involve inhibition of MLCK activity itself.
TNFAIP3 deubiquitinates non-K48-linked
polyubiquitinated occludin
The ability ofTNFAIP3 to regulate TJ dynamics,butnot MLCK
activity, suggests that TNFAIP3 might act on the TJ itself. The
enzymatic activity of TNFAIP3 may directly or indirectly alter the
ubiquitination of TJ proteins, such as occludin. Ubiquitination of
occludin mediates its endocytosis, thus increasing permeability of
the tight junction [13]. To determine whether TNFAIP3 associates
with occludin in cells, we immunoprecipitated endogenous
TNFAIP3 and tested for the presence of associated occludin.
TNFAIP3 and occludin were associated in unstimulated cells and
this association was diminished 10 minutes after stimulation with
TNF. Thus, TNFAIP3 and occludin associate in cells in a manner
that is regulated by TNF stimulation (Figure 7A). To determine
whether TNFAIP3 can deubiquitinate occludin, we incubated
recombinant N-terminal TNFAIP3 with ubiquitinated occludin in
vitro. We found that TNFAIP3 was able to decrease the total
ubiquitination of occludin (Figure 7B). In addition we transfected
epitope-tagged forms of TNFAIP3, occludin, and K48R-ubiquitin
into HEK 293T cells. The mutation in ubiquitin from a lysine to
arginine at position 48 prevents degradative polyubiquitin chains
from forming on substrates; thus, the Myc-epitope tag will mark
only mono, K63-linked and other non-K48-linked polyubiquitin
chains. The introduction of an increasing amount of TNFAIP3 into
cells resulted in decreased ubiquitination of co-transfected occludin
(Figure 7B). These results indicate that TNFAIP3 can alter the
ubiquitination of occludin, and are consistent with the retention of
occludin at the apical membrane in the intestines of LPS-treated
villin-TNFAIP3 mice.
Discussion
Our results demonstrate that TNFAIP3 is required to maintain
barrier function in the intestine and that TNFAIP3 plays a direct
role in IECs to control TNF-induced increases in IEC tight
Figure 4. Intestinal epithelial cell-specific expression of TNFAIP3 protects against LPS-induced disruption of tight junctions.
Immunohistochemistry showing occludin (green), actin (red) and DNA (blue) localization in the intestinal epithelium of untreated (upper two panels)
or LPS-treated (lower four panels; 0.1 mg/mouse, ,5 mg/kg i.p.) mice is displayed. (Upper four panels 40X objective lens; lower two panels 100X
objective lens).
doi:10.1371/journal.pone.0026352.g004
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TNFAIP3 maintains occludin localization at the apical mem-
brane, potentially through regulation of its ubiquitination. This
suggests that the role of TNFAIP3 in barrier function may result
from direct action on the tight junction. The importance of
TNFAIP3 in intestinal epithelial cells and cell lines has previously
been demonstrated. Lineage specific deletion of TNFAIP3
sensitizes IECs to TNF-induced apoptosis in vivo, and TNFAIP3
regulates IEC NF-kB activation in response to TNF and TLR
ligands in vitro [22,23,47,48]. However, our findings describe for
the first time a role for TNFAIP3 in the maintenance of IEC tight
junctions. Thus, TNFAIP3 may play multiple roles in the
regulation of IEC homeostasis including the control of NF-kB
activity, apoptosis, and TJ integrity.
TNFAIP3 was initially cloned from TNF-stimulated human
umbilical vein endothelial cells and was subsequently found to have
limited mRNA expression in mouse and human tissues [49].
However, TNFAIP3 is a strongly NF-kB-induced gene in almost all
tissues and cell types following exposure to TNF or other NF-kB-
activating ligands [19,21]. Thus, TNFAIP3 likely has essential
functions in multiple cell types in vivo. We observed decreased barrier
function inTNFAIP3
2/2 mice, which may reflect a primary role for
TNFAIP3 in IECs or a secondary effect of increased activation of
immune cells in the mucosa of these mice. It is likely that TNFAIP3
plays critical roles in both epithelial cells and immune cells to control
barrierfunction.Theintestinalmucosaiscontinuouslychallengedby
microbial ligands that can activate innate immune TLRs to induce
inflammation. Mice adoptively transferred with TNFAIP3
2/2 x
Myd88
2/2hematopoieticstem cellsdisplaydecreased inflammatory
activation in the intestine demonstrating that the control of immune
cell TLR signaling by TNFAIP3 is also required for intestinal
homeostasis[39].It hasnotbeendeterminedwhetherTNFAIP3
2/2
mucosal immune cells cause decreased IEC barrier function, but
TNFAIP3
2/2 immune cells produce higher amounts of TNF [17].
Therefore, decreased barrier function resulting from the lack of
TNFAIP3 in immune cells is one likely contributor to the disrupted
IEC barrier we have observed in TNFAIP3
2/2 mice. However,
TNFAIP3 overexpression in IECs attenuates LPS-induced barrier
loss in vivo and TNF-induced decreases in TER in vitro.T h i s
highlights the unique contribution of TNFAIP3 expression in IECs
in directly controlling intestinal barrier function.
Figure 5. TNFAIP3 regulates TNF-induced tight junction
dynamics in intestinal epithelial cells. Transepithelial electrical
resistance (TER) was measured serially in cells grown in semi-permeable
supports untreated (open symbols) or treated with TNF (10 ng/ml;
closed symbols) for the indicated times. Values represent percentage of
initial resistance measurements (% Init V). Pools of cells were stably
transduced with (A) GFP alone (GFP control; triangles) or GFP and
TNFAIP3 (TNFAIP3 +++; squares); or (B) scrambled shRNA (control
shRNA; triangles) or TNFAIP3 shRNA (circles). (**p,0.01, ***p,0.001;
TNF-treated GFP controls vs. untreated GFP controls (A) or TNF-treated
control shRNA/TNF-treated TNFAIP3 shRNA vs. their respective untreat-
ed lines (B)).
doi:10.1371/journal.pone.0026352.g005
Figure 6. TNFAIP3 regulates an MLCK-dependent signal, but
does not control MLCK activity. (A) TER measurements of stably
transduced pools of cells expressing scrambled shRNA (control shRNA;
triangles) or TNFAIP3 shRNA (circles) were treated with TNF alone
(10 ng/ml; open symbols) or TNF plus the cell permeant MLCK inhibitor
PIK (200 mM; closed symbols). Values represent percentage of initial
resistance measurements (% Init V). (***p,0.001; TNF vs. TNF+PIK
treated) (B) Immunoblot of phospho-MLC levels using whole cell lysates
from GFP transduced (WT), or GFP together with TNFAIP3 transduced
(TNFAIP3 +++) cells treated with TNF (10 ng/ml) for the indicated times
minutes.
doi:10.1371/journal.pone.0026352.g006
TNFAIP3 and Tight Junctions
PLoS ONE | www.plosone.org 5 October 2011 | Volume 6 | Issue 10 | e26352Figure 7. TNFAIP3 associates with and deubiquitinates occludin. (A) Immunoblot of occludin in TNFAIP3 immunoprecipitates from HCT116
cells with and without TNF stimulation. (B) Immunoblot for ubiquitin (upper panel) or occludin (center panel) from an in vitro DUB assay with non-
K48-linked polyubiquitinated occludin and increasing amounts of recombinant N-terminal (DUB domain only, residues 1–371) TNFAIP3 (0, 5, 10,
20 mM) or isopeptidase T as a positive control (0.5 mM). Ubiquitinated occludin immunoprecipitated from transfected HEK 293T cells was mixed with
enzyme for 24 hours and the reaction products were resolved by SDS-PAGE and analyzed for ubiquitination. The lower panel shows an immunoblot
from the reaction supernatant (Sup) indicating the relative amount of TNFAIP3 present at the end of the assay. (C) Immunoblot from an in vivo DUB
assay showing the ubiquitination of occludin in cells co-transfected with plasmids that express K48R-ubiquitin (0.5 mg), occludin (3 mg), and
increasing amounts of full-length TNFAIP3 (0, 1, 5, 10 mg). The upper two panels are immunoblots of lysates immunoprecipitated with antibody
against the V5-epitope tag (IP: V5-occludin), and the lower two panels are immunoblots of whole cell lysates (Pre-IP). In panels B and C, the inset
numbers in white are the densitometry of the ubiquitin in each lane.
doi:10.1371/journal.pone.0026352.g007
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TNFAIP39s N-terminal DUB activity. This indicates that
TNFAIP3 may limit the endocytosis of occludin caused by
cytokine exposure and mediated by polyubiquitination [13].
TNFAIP3 DUB activity removes K63-linked chains from NF-kB
signaling molecules such as RIP1, RIP2, TRAF2 and TRAF6;
however, TNFAIP3 does not have preferential specificity for K63-
linked chains [21]. The DUB domain recognizes polyubiquiti-
nated substrates and deubiquitinates them, with higher-order
ubiquitinated species more susceptible to cleavage [50]. Therefore,
it is plausible that TNFAIP3-mediated ubiquitin editing contrib-
utes to the modification of tight junction proteins. We also
observed association between endogenous TNFAIP3 and occludin
that was rapidly diminished by TNF stimulation in WT cells. It is
not known how occludin and TNFAIP3 associate with each other
in cells, but both proteins are known to associate with ITCH,
suggesting that TNFAIP3 and occludin may associate indirectly
through ITCH. Interestingly, occludin can be polyubiquitinated
by ITCH, an E3 ligase dependent on occludin phosphorylation at
Ser-490 [51,52]. ITCH-mediated occludin ubiquitination has
been described in Sertoli cell TJ disruption after dibutyryl-cAMP
treatment and in bovine retinal epithelial cells upon treatment
with VEGF [13,53]. Alternatively, ITCH may also facilitate
deubiquitination of substrates by TNFAIP3, as ITCH
2/2 cells
display prolonged TRAF6 ubiquitination following IL-1 stimula-
tion [52,54]. Further studies are necessary to determine whether
TNFAIP3 and ITCH work together to regulate the ubiquitination
status of occludin, or act independently of one another. The
kinetics of TJ opening in our studies suggest that TNFAIP3 must
act rapidly to control this process. TNFAIP3 is rapidly induced by
NF-kB and feeds back to deubiquitinate RIP within 30 minutes of
stimulation and to stop NF-kB activation within 60 minutes of
TNF treatment [18,19]. Additionally, TNFAIP3 is phosphorylated
within 15 minutes of TNF treatment, and this enhances the ability
of TNFAIP3 to regulate NF-kB activation [55]. Thus TNFAIP3
associates with occludin and can deubiquitinate occludin. The
rapid kinetics of TNFAIP3 regulation of other signaling pathways
suggest that TNFAIP3 may control occludin ubiquitination with
similar kinetics.
TNFAIP3 can inhibit both NF-kB signaling and apoptosis, but
the role of TNFAIP3 in vivo is likely cell and context dependent,
owing to the ability of NF-kB to concomitantly induce
transcription of inflammatory and anti-apoptotic genes. In most
cell types, stimulation with TNF will initiate an apoptotic pathway
as well as expression of opposing NF-kB-driven anti-apoptotic
genes. TNFAIP3 is one such anti-apoptotic gene, which in many
cell types is required to prevent apoptosis, even in the setting of
enhanced NF-kB activation [19]. Conversely, the loss of TNFAIP3
in B cells renders them less susceptible to apoptosis, owing to
enhanced activation and production of other NF-kB-driven anti-
apoptotic proteins in that cell type [56]. The role of TNFAIP3 in
IECs appears best described by the former scenario, as mice with
IEC-specific deletion of TNFAIP3 are sensitive to TNF-induced
apoptosis and intestinal inflammation [22]. NF-kB activation is
also essential for survival of intestinal epithelial cells in response to
TNF, as mice lacking IKK activity display TNF-dependent IEC
apoptosis and intestinal inflammation [57]. While this is likely due,
at least in part, to NF-kB-induced expression of TNFAIP3, it
remains to be determined whether IEC-specific expression of
TNFAIP3 alone can rescue mice from the phenotype observed in
the absence of IEC NF-kB activity. In vitro, cells typically do not
undergo apoptosis when exposed to TNF alone, but require
additional stressors like the concurrent addition of cycloheximide
to block new protein synthesis. Consistent with this, we did not
observe changes in apoptosis in cells expressing increased or
diminished TNFAIP3 in our studies to assess TER following short-
term treatment with TNF alone. When cells were treated with
TNF and cycloheximide, for longer periods of time, the anti-
apoptotic function of TNFAIP3 was evident in vitro (Figure S4).
Our results suggest that in addition to regulating NF-kB and
apoptosis, TNFAIP3 may have unique functions in IEC that
promote intestinal homeostasis; namely the inhibition of TNF-
induced TJ disassembly.
The overexpression of TNFAIP3 in IEC may be an attractive
goal for control of intestinal inflammation in the context of human
disease, as this may block both NF-kB signals and apoptosis while
also preventing the loss of barrier function. The novel role of
TNFAIP3 in intestinal barrier function may have consequences for
inflammation in other tissues as well, as barrier function and
TNFAIP3 genetic variants have both been implicated in multiple
autoimmune disorders. Although the immune system plays a
major role in inflammatory disease pathogenesis, intestinal
permeability may also lead to inflammatory disease. There is
precedent in mouse models and humans with IBD, that gut
permeability precedes the onset of inflammation [58] [3,9] [59].
Genetic variations in TNFAIP3 that confer loss of enzymatic
function or expression may lead to IBD in part by altering
TNFAIP39s function in IEC, thereby leading to increases in
intestinal permeability and disruption of intestinal homeostasis
[30]. Indeed, mucosa taken from Crohn’s disease patients with
moderate to severe disease is characterized by low expression of
TNFAIP3 [25]. Further, the lack of intestinal barrier function may
impact other organs leading to, for example, diabetes or lupus, as
well as other extraintestinal inflammatory disorders [60–62]. Thus,
variations to TNFAIP39s function as a barrier protein may have
wide-ranging effects including the regulation of intestinal perme-
ability, the innate immune system, and other organ systems.
Materials and Methods
Materials
Recombinant human TNF-a was from Peprotech (Rocky Hill,
NJ). Myosin Light Chain Kinase inhibitor PIK was generated as
described [46]. Cytokine response modifier A (CrmA) and pCMV-
Myc-K48R-ubiquitin expression plasmids were generous gifts
from M. Peter and C. Maki, respectively (University of Chicago,
Chicago, IL). The complete murine TNFAIP3 coding sequence
was PCR cloned from C57BL/6 cDNA into pCMV-Tag2
(mammalian expression vector containing an N-terminal Flag-
epitope tag from Stratagene, La Jolla, CA). Human recombinant
N-terminal A20 (TNFAIP3 catalytic DUB domain) and Isopepti-
dase T were from Boston Biochem (Cambridge, MA). Antibodies
for western blotting included primary antibodies anti-V5, anti-
Myc, and anti-occludin (Invitrogen, Carlsbad, CA), anti-actin and
anti-HA (Santa Cruz Biotechnology, Santa Cruz, CA), anti-FLAG
(Sigma-Aldrich, St. Louis, MO), anti-phospho-MLC (Cell Signal-
ing, Danvers, MA), and anti-TNFAIP3 (generous gift from A. Ma,
University of California, San Francisco, CA). Fluorescently tagged
secondary antibodies included alexa-Fluor 680, 488, and 555
(Invitrogen) and IRdye 700 and 800 (Rockland Immunochemicals,
Gilbertsville, PA).
Generation of TNFAIP3-deficient and Villin-TNFAIP3
Transgenic Mice
The generation and characterization of TNFAIP3-deficient
mice has been previously described [19]. Villin-TNFAIP3
transgenic mice were generated by galK-based recombineering
(as described in [63]) of the murine BAC clone RP23-278N11, a
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flanking genomic sequence (Figure S1). Full-length mouse
TNFAIP3 cDNA containing an N-terminal FLAG-epitope tag
was PCR-amplified from the pCMV-Tag2 vector described above.
The final transgenic construct sequence includes 17,780 bp of
promoter sequence directly upstream of the ATG start site in the
villin gene, and measures 31,815 bp in length. The final villin-
TNFAIP3 construct was digested with SalI (New England
BioLabs, Ipswich, MA), and a 23,376bp linearized fragment was
microinjected into C57BL/6 oocytes (University of Chicago
Transgenics/ES Cell Technology Mouse Core). The transmission
and expression of the transgene was confirmed in three
independent lines by Southern and Northern blot analyses of
mouse intestinal tissue (Figure S2). Intestinal epithelial cells from
mice were isolated as described [64]. All experiments were
performed with mice on a C57BL/6 background using age- and
sex-matched littermate controls. All mice were housed in a specific
pathogen-free facility, and the Institutional Animal Care and Use
Committee at the University of Chicago approved all mouse
experiments (protocol #71661 and #72089).
Cell Culture
All experiments were performed on HCT116 cells (human
colorectal carcinoma cell line; ATCC #CCL-247) and HEK
293T/17 cells (human embryonic kidney cell line; ATCC #CRL-
11268). HCT116 cells were maintained in McCoy’s 5A Media and
HEK 293T cells were maintained in Dulbecco’s Modified Eagle
Medium; both supplemented with 10% (volume/volume) fetal
bovine serum, and penicillin (50 units/ml)/streptomycin (50 mg/
ml) (Invitrogen). Trypsin-EDTA, phosphate buffered saline (PBS),
and related cell culture reagents were from Invitrogen. Cells were
incubated at 37uCi n5 %C O 2 with medium changed every 2–3
days. For growth as polarized monolayers, cells were plated on
collagen-coated inserts (0.4 mm pore polycarbonate, BD Biosci-
ences, Bedford, MA) and grown on these semi-permeable supports
for 21 days past confluence in McCoy’s 5A Media, supplemented
with 30% (volume/volume) fetal bovine serum and penicillin (50
units/ml)/streptomycin (50 mg/ml) (changed daily).
TNFAIP3 expressing cell lines
HCT116 cell lines constitutively expressing TNFAIP3 or
TNFAIP3 shRNA were developed using lentiviral transduction
with vectors generously provided by Didier Trono (Ecole
Polytechnique Fe ´de ´rale de Lausanne, Switzerland). Lentivirus
was generated in HEK 293T cells by co-transfecting three
plasmids (pTAT, pMD2.G, and p89.1) containing necessary viral
machinery and a fourth plasmid (pWPI or pLVTHM) containing
the murine TNFAIP3 cDNA or shRNA respectively, along with
an IRES-GFP. For the control cell lines, the parental pWPI vector
or pLVTHM containing scrambled shRNA were used to generate
virus encoding only GFP- or scrambled shRNA-expressing cells,
respectively. The validated TNFAIP3 and scrambled shRNA
constructs were from OriGene (Rockville, MD). Virus-containing
supernatant from transfected HEK 293T cells was collected and
applied to HCT116 cells. Infected, stable pools of HCT116 cells
were subsequently sorted for GFP signal to greater than 95%
purity by flow cytometry using the Dako Cytomation MoFlo-HTS
(Carpinteria, CA).
Intestinal Permeability Assay
To assess intestinal permeability we utilized a mouse ex vivo
intestinal loop model previously described [65,66]. For villin-
TNFAIP3 transgenic studies, mice were injected intraperitoneally
(i.p.) with 0.1 mg/mouse (,5 mg/kg) LPS (Sigma-Aldrich) 45
minutes prior to euthanasia. Explanted intestinal segments were
filled with dialyzed FITC-dextran (1 mg/mL, molecular weight
4,000, Sigma-Aldrich) in PBS, ligated at the ends with sutures,
transferred into wells containing 2 mL PBS, and incubated at
37uC. To determine FITC-dextran flux across the loops, the wells
were sampled at each timepoint and fluorescence was measured
using BioTek Synergy2 plate reader (Winooski, VT). FITC-
dextran flux was calculated as the change in fluorescence per cm of
intestine over time.
Immunohistochemistry
Immunohistochemistry was performed on frozen intestinal
sections (5 mm) embedded in O.C.T. Compound (Sakura Finetek,
Torrance, CA). Samples were hydrated via successive PBS washes
and blocked with 5% BSA in a humidified chamber (45 minutes,
20uC) before incubation with primary antibodies (0.4 mg/ml -
2 mg/ml in 2.5% BSA, 18 h, 4uC). Samples were washed the
following day with PBS, incubated with fluorescent secondary
antibody (0.1 mg/ml in PBS) and Hoechst stain (2 mg/ml). Stained
samples were mounted in ProLong Antifade (Invitrogen) and
photographed using a fluorescence microscope (DM2500, Leica
Microsystems, Buffalo Grove, IL).
In vitro Transepithelial Electrical Resistance
TER was measured in cells grown to 21 days post confluence in
semi-permeable supports (0.4 mm pore collagen-coated filters)
using an EVOM epithelial voltohmmeter (World Precision
Instruments, Sarasota, FL). All samples were given fresh media
prior to the first TER measurement. TNF treatments (10 ng/mL)
were administered basolaterally, while PIK (200 mM) treatments
were given apically. TER readings were taken from two different
areas of each culture well and averaged to account for variability.
An empty culture well filled with the appropriate amount of media
was used in each experiment to determine the approximate
resistance contribution from the membrane support and media
alone.
TNFAIP3 cell death assays
TNFAIP3 overexpressing, TNFAIP3 deficient, and control lines
derived from human HCT116 IECs were grown to confluency on
standard 6-well tissue culture plates and treated with 0 or 10 ng/
ml TNF, with or without 25 mg/ml cycloheximide (Sigma-
Aldrich). Cells were harvested 3 hours post-treatment using
Accutase (Innovative Cell Technologies, San Diego, CA) and
incubated with 50 mg/ml propidium iodide (Invitrogen) and
annexin V-biotin with streptavidin-APC (BD Pharmingen, San
Diego, CA). Cell suspensions were analyzed by flow cytometry on
a BD FACSCalibur (BD Biosciences) to detect cell death as
indicated by PI
+ or annexin V
+/PI
+ cells.
Transfection, Immunoprecipitation and Western Blot
Analysis
Transient transfections were performed as previously described
[35]. For K48R-polyubiquitinated occludin immunoprecipitation
(IP) studies, lysates were incubated 2 hours at 4uC with a 50%
slurry of anti-V5 Ab conjugated to Protein G agarose beads (Pierce
Biotechnology, Rockford, IL). Beads were recovered, washed 3
times with lysis buffer (1% Triton, 10% glycerol, 50 mM HEPES,
150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, and 1% Triton X-
100), and mixed with equal volume 26Laemmli reducing buffer
and boiled (100uC, 5 minutes). For phospho-MLC analysis, HCT
116 cells (GFP control and TNFAIP3 overexpressing) were treated
with 10 ng/ml TNF for 30 minutes, lysed directly in Laemmli
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SDS-PAGE (4–12% Bis-Tris NuPAGE acrylamide gel from
Invitrogen) and transferred to polyvinylidene fluoride (PVDF)
membranes (Millipore, Billerica, MA) using NuPAGE transfer
buffer and an XCell-II blot module (Invitrogen), and then
immunoblotted with the indicated primary antibodies. Fluores-
cent-labeled secondary antibodies were then applied and the blots
were visualized using the Odyssey Imaging System (LI-COR
Biosciences, Lincoln, NE).
In vitro Deubiquitination Assays
For cell-free in vitro deubiquitination assays of immunopre-
cipitated occludin, HEK 293T cells were transfected with V5-
occludin (3 mg), Myc-K48R-ubiquitin (1 mg) and CrmA (0.5 mg)
for 48 hours, lysed and immunoprecipitated as described
[17]. Beads were washed with lysis buffer, PBS, and then incubated
24 hours at 37uC with recombinant N-terminal TNFAIP3 (5,
10, or 20 mM) or Isopeptidase T (0.5 mM) in enzyme buffer
(300 mM NaCl, 20 mM Tris, 10 mM DTT). Ubiquitination levels
were assessed by SDS-PAGE and immunoblotting as described
above.
Statistical Analysis
All experiments were performed at least three times unless
otherwise indicated. Results shown are the means and standard
deviation of all samples taken. Statistical significance was
determined using ANOVA with post-hoc Bonferroni adjustment
using GraphPad Prism software (La Jolla, CA) and significance
was inferred with p-values less than 0.05.
Supporting Information
Figure S1 Generation of the villin-TNFAIP3 transgenic
construct. Plasmid maps for generation of the villin-TNFAIP3
transgenic construct made using galK-based recombineering on the
murine BAC clone RP23-278N11, a 193,097 bp construct
containing the villin gene, the complete villin promoter, and
adjacent genomic sequence. The parental BAC was trimmed
down to contain 17,780 bp of promoter sequence upstream of the
ATG start site of the villin gene. Full-length mouse TNFAIP3
cDNA containing an N-terminal FLAG-epitope tag was inserted
in place of the villin coding sequence. The final transgenic
construct measures 31,815 bp in length.
(TIF)
Figure S2 TNFAIP3 expression in villin-TNFAIP3 mice.
(A) Northern blot analysis of TNFAIP3 mRNA expression in
tissues (S, spleen; I, small intestine) from untreated or LPS-injected
(0.1 mg/mouse, ,5 mg/kg i.p.) WT or villin-TNFAIP3 transgenic
mice. Endogenous and transgenic TNFAIP3 mRNA can be
differentiated based on size, and the location of each band is
indicated in the upper panel. Total GAPDH message is shown in
lower panel as a loading control. (B) Western blot showing IEC
isolated from two WT (-) and three villin-TNFAIP3 transgenic (+)
mice. Lysed IEC were immunoprecipitated (IP) with an antibody
against the FLAG-epitope tag and immunoblotted for FLAG to
show the relative overexpression of TNFAIP3 protein in the
intestine of untreated villin-TNFAIP3 transgenic mice. Whole cell
lysates (Pre-IP) were blotted for actin in the lower panel.
(TIF)
Figure S3 Generation of TNFAIP3 overexpressing and
TNFAIP3 knock-down cell lines. (A) Immunoblots of whole
cell lysates from sorted HCT116 IEC lines infected with lentivirus
containing GFP only (WT) or GFP together with TNFAIP3
(TNFAIP3 +++). The upper panel shows the total amount of
overexpressed TNFAIP3 (center band), and the lower panel shows
total actin levels. (B) HEK 293T cells were transiently co-
transfected with V5-TNFAIP3 along with a scrambled negative
control shRNA construct (control), or one of five different
TNFAIP3 shRNA constructs (898, 899, 900, 901, 902, or 903).
The upper panel shows TNFAIP3 expression in whole cell lysates
immunoblotted for the V5-epitope tag. Expression of V5-
TNFAIP3 is most effectively reduced using TNFAIP3 shRNA
902 (marked with an asterisk). The TNFAIP3 shRNA 902
construct was then used to make lentivirus in order to generate
stable HCT116 IEC lines with knocked down expression of
TNFAIP3. The lower panel shows whole cell lysates immuno-
blotted for actin.
(TIF)
Figure S4 TNF alone is not sufficient to induce cell
death in TNFAIP3 overexpressing or TNFAIP3 knocked-
down IECs. Cells were treated for 3 hours with 10 ng/ml TNF
(+ TNF) or without (- TNF), and with 25 mg/ml cycloheximide (+
CHX) or without (- CHX). Cell death was measured using
annexin V and PI. The dot plots have been gated on only GFP
positive cells. The percentage of these GFP positive cells that are
both annexin V positive and PI positive, or only PI positive are
indicated in the quadrants and represent the cells undergoing cell
death. The frequency of cell death is compared between control
HCT116 cells expressing GFP alone (GFP Control) or TNFAIP3
overexpressing (TNFAIP3 +++) cell lines in (A), and between
scrambled shRNA-expressing cells (Control shRNA) and
TNFAIP3 shRNA-expressing cells in (B).
(TIF)
Figure S5 The MLCK inhibitor PIK does not inhibit
TNFAIP39s deubiquitinating activity. Recombinant N-
terminal TNFAIP3 was incubated (12h, 37C) with ubiquitin
chains (a mixture of di-, tri-, and tetra-ubiquitin chains) in vitro and
reaction products were resolved by SDS-PAGE and visualized
with silver staining. Deubiquitinating activity of TNFAIP3 was
evident by the degradation of ubiquitin to form monomeric
ubiquitin. This activity was inhibited by the cysteine protease
inhibitor N-ethylmaleimide (NEM) but not by the MLCK
inhibitor PIK.
(TIF)
Figure S6 PIK does not significantly alter TER in
untreated cells. Cells expressing TNFAIP3 shRNA or control
(scrambled) shRNA were treated with the MLCK inhibitor PIK
and assessed for TER as described in Figure 6.
(TIF)
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